UK telehealth brands looking at US and EU expansion face fundamentally different regulatory landscapes in each region. US is state-by-state. EU is country-by-country. Both are bigger than the UK individually; neither is a copy-paste expansion. This piece is a structural map for UK brands evaluating international expansion in 2026 and 2027.
Why brands cross borders — TAM, margin, brand defensibility
Three reasons drive international expansion. TAM: the UK private telehealth market is meaningful but smaller than US or EU. Margin: certain categories have better unit economics in other markets. Brand defensibility: building international presence creates moats that pure-UK competitors struggle to match. Pick the reason that's actually driving you — it shapes the expansion approach.
US — state-board telehealth landscape, the 50-state problem
US telehealth is regulated state-by-state, not federally, requiring prescriber licensure in each state of practice. The 50-state problem is real. Practical strategies: launch in a small number of states (typically the largest by population), use a prescriber network with multi-state licensure, partner with US infrastructure rather than building. The compliance landscape is denser than UK GDPR + GPhC combined.
EU — national pharmacy authorities, language, payments
EU pharmacy regulation is national. Germany (BfArM), France (ANSM), Spain (AEMPS), Netherlands (CIBG) each apply separately. Language localisation matters. Payment systems vary (SEPA, local card networks, BNPL providers). Clinical pathways differ. The EU is not one market — it is 27 countries with reciprocal arrangements in some areas and divergent rules in others.
Data residency and cross-border patient data flow
Cross-border patient data transfers from the UK to the EU rely on the UK adequacy decision in force since 2021. UK-to-US transfers require Standard Contractual Clauses or equivalent mechanisms. Operating across regions requires data architecture that respects each jurisdiction's residency expectations — usually solved by regional data warehousing.
Operational model — partner-per-region vs central platform
Most UK brands expanding internationally choose a partner-per-region model in years 1-2 before centralising. The partner-per-region model trades commercial efficiency for regulatory simplicity — each region's compliance lives with a local partner. The centralised model is faster operationally but requires deep regulatory expertise upfront. Pick based on capital, founder bandwidth, and time-to-launch priorities.
Realistic timeline and capex for entering each region
Realistic expansion timeline: US — 6-12 months from decision to first patient in initial states; full multi-state coverage 18-36 months. EU — 6-9 months per priority country; multi-country coverage 18-30 months. Capex varies wildly; partner-led models typically £100k-£500k per region in setup, central-model builds £1M+ per region.
US telehealth is regulated state-by-state, not federally. Prescriber licensure in each state of practice is non-negotiable. The 50-state problem is the structural challenge of US expansion.
The EU is not one market — it is 27 countries with reciprocal arrangements in some areas and divergent rules in others.
International expansion from a UK telehealth base is achievable but not trivial. The brands that succeed pick the right reason, the right region, and the right operational model — and budget for the regulatory complexity. The ones that don't treat expansion as marketing rather than operations and stumble accordingly.
